You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: PROTEIN METRICS INC            Topic: 400

    Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growthTo datesmall molecule inhibitors of MYC have remained elusiveIn our Phase I STTRCAwe developed a lead compoundSFwhich displays potent orthogonal inhibitory acti ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD BIOTHERAPEUTICS INC.            Topic: NIDDK

    DESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells

    SBC: CELL MICROSYSTEMS INC            Topic: NIAID

    Project SummaryAdoptive cell therapyACTis an emerging immunotherapy which shows significant promise in treating both leukemia and solid tumorsas well as certain infectious diseasesACT comprises the isolation and ex vivo expansion of cytotoxic T lymphocytesCTLsrecognizing epitopes of a mutated or aberrantly expressed protein present almost exclusively on the surface of a patient s tumor cellsTo mee ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Augmenting Dual Energy CT for Novel Contrast Agents

    SBC: NEXTRAST, INC            Topic: 300

    Project SummaryAbstract Our long term goal is to revolutionize the effectiveness of CT imaging for millions of Americans across a broad range of abdominal diseaseDual energy CTDECTprovides powerful clinical diagnostic potential but remains heavily underutilized despite wide scanner availabilityDECT allows materials to be differentiated based on their relative X ray attenuation at low versus high e ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    AbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development of user-friendly fluorescence based assays for marine toxins

    SBC: SeaTox Research Inc            Topic: 113

    ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Microfluidic Nitric Oxide Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    PROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Study of CdZnTe Electrode Interface and Fabrication Technology Development

    SBC: Aguila Technologies, Inc.            Topic: N/A

    Not avaiable.

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government